CA2848765A1 - Immunotherapy and diagnosis of mucormycosis using coth - Google Patents

Immunotherapy and diagnosis of mucormycosis using coth Download PDF

Info

Publication number
CA2848765A1
CA2848765A1 CA2848765A CA2848765A CA2848765A1 CA 2848765 A1 CA2848765 A1 CA 2848765A1 CA 2848765 A CA2848765 A CA 2848765A CA 2848765 A CA2848765 A CA 2848765A CA 2848765 A1 CA2848765 A1 CA 2848765A1
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
seq
coth
mucorales
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2848765A
Other languages
English (en)
French (fr)
Inventor
Ashraf S. Ibrahim
Mingfu Liu
Teklegiorgis GHEBREMARIAM
Yue Fu
John E. Edwards
Scott Filler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center filed Critical Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Publication of CA2848765A1 publication Critical patent/CA2848765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2848765A 2011-09-15 2012-09-14 Immunotherapy and diagnosis of mucormycosis using coth Abandoned CA2848765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535257P 2011-09-15 2011-09-15
US61/535,257 2011-09-15
PCT/US2012/055659 WO2013040517A2 (en) 2011-09-15 2012-09-14 IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH

Publications (1)

Publication Number Publication Date
CA2848765A1 true CA2848765A1 (en) 2013-03-21

Family

ID=47884011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848765A Abandoned CA2848765A1 (en) 2011-09-15 2012-09-14 Immunotherapy and diagnosis of mucormycosis using coth

Country Status (7)

Country Link
US (3) US9279002B2 (enExample)
EP (1) EP2755681B1 (enExample)
JP (1) JP2014528715A (enExample)
CN (1) CN103998057A (enExample)
AU (1) AU2012308240A1 (enExample)
CA (1) CA2848765A1 (enExample)
WO (1) WO2013040517A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465233B2 (en) * 2016-03-25 2019-11-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Time-resolved nucleic acid hybridization beacons
EP3454944B1 (en) * 2016-05-13 2022-07-13 The Brigham and Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
US10877037B2 (en) 2016-11-21 2020-12-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Fungal toxins and methods related to the same
WO2022236145A1 (en) * 2021-05-06 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Coth3 binding agents and uses thereof
CN114324896A (zh) * 2021-12-31 2022-04-12 菲鹏生物股份有限公司 特异性结合mucoricin蛋白的试剂的用途和毛霉菌检测试剂盒
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2561478B2 (ja) 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1990006997A1 (en) 1988-12-13 1990-06-28 United States Government As Represented By The Secretary Of The Department Of Health And Human Services Genetically engineered endothelial cells and use thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH06500923A (ja) 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
WO1992007573A1 (en) 1990-10-31 1992-05-14 Somatix Therapy Corporation Genetic modification of endothelial cells
JP3547129B2 (ja) 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
GB0205378D0 (en) * 2002-03-07 2002-04-24 Royal Holloway University Of L Bacterial spores
EP2049669A2 (en) * 2006-08-09 2009-04-22 DSMIP Assets B.V. Spore surface displays of bioactive molecules
US8697374B2 (en) * 2008-02-28 2014-04-15 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
NZ614255A (en) * 2009-03-19 2015-03-27 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US20110059111A1 (en) * 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections

Also Published As

Publication number Publication date
JP2014528715A (ja) 2014-10-30
US9279002B2 (en) 2016-03-08
EP2755681A2 (en) 2014-07-23
AU2012308240A1 (en) 2013-05-02
EP2755681A4 (en) 2015-05-13
US20190194301A1 (en) 2019-06-27
WO2013040517A3 (en) 2013-07-18
US20130108642A1 (en) 2013-05-02
WO2013040517A2 (en) 2013-03-21
US20160159887A1 (en) 2016-06-09
CN103998057A (zh) 2014-08-20
EP2755681B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
US20190194301A1 (en) Immunotherapy and diagnosis of mucormycosis using coth
CA2372821C (en) Antimicrobial theta defensins and methods of using same
US20120014995A1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP1636269A2 (en) Extracellular aspergillus polypeptides
AU2016244238A1 (en) Hyr1 as a target for active and passive immunization against candida
CN106279423B (zh) Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用
US20160130330A1 (en) Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
US20100330070A1 (en) Methods Of Making An Antibody And Compositions Thereof
AU2006244401B2 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060241288A1 (en) Extracellular aspergillus polypeptides
US20020034751A1 (en) Aspergillus fumigatus antigenic protein 1
JP5925783B2 (ja) アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
WO2003018629A1 (en) Cage antigen
CN1948335B (zh) 白念珠菌菌丝调控因子基因及其用途
JP5573679B2 (ja) マラリアワクチン組成物および細胞媒介免疫性を惹起する成分
US6638734B1 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US20030092083A1 (en) Cage antigen
KR101683002B1 (ko) 국균증 또는 아스퍼질루스증 치료를 위한 유전자 sppA 및 단백질 SppA의 용도
CN100480379C (zh) 白念珠菌ctd蛋白激酶基因及其用途
WO2005071070A2 (en) Substances directed against specific sequence essential for heparanase catalytic activity end uses thereof as heparanase inhibitors
WO2000077207A2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
CN106699892B (zh) 肺鳞癌中dnah5融合基因及其用途
CN101638624A (zh) 白念珠菌的菌丝发育相关基因及其用途
CN103059110A (zh) 白念珠菌细胞凋亡促进因子基因及其用途
WO1999040199A2 (en) A novel fungal protein critical for expression of fungal proteins

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170914